News Sentiment

PEN sentiment intelligence

Penumbra Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 61 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 318.10 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

75/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

-0.1% over one week, -0.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Analyst Report: Penumbra, Inc.

Market Reaction

Balanced read

52/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 75/100 classification
One-week reaction -0.1% Price digesting
Trend fit Trend inactive -0.2% over four weeks
Fair value 23.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 49
Negative 0

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 10
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
TradingView 9
simplywall.st 4
Stock Titan 4
Morningstar 3
Stock Traders Daily 2
MedTech Dive 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 22
Deals and strategy 6
Analyst action 3
Regulatory and legal 3
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
Morningstar Research Direct company coverage

Analyst Report: Penumbra, Inc.

Tone
Neutral 50/100
Event
Analyst action
Published
17 Jul 2026 14:51
Source
Morningstar Research
Morningstar Direct company coverage

Risk of Antitrust Challenges Remains Low for Boston's Acquisition of Penumbra

Morningstar analyst Debbie S. Wang reiterated that the risk of antitrust challenges for Boston Scientific's planned acquisition of Penumbra remains low. The article highlights Penumbra's history of creating innovative endovascular devices for blood clots and aneurysms, positionin

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jul 2026 15:10
Source
Morningstar
Moomoo Direct company coverage

Penumbra (PEN) Stock Forum and Discussion

This article provides a forum and discussion board for Penumbra (PEN) stock. It allows investors to share insights and engage in discussions about the company's performance, news, and future outlook. The content is primarily user-generated, focusing on various aspects relevant to

Tone
Neutral 50/100
Event
Guidance
Published
15 Jul 2026 09:41
Source
Moomoo
Stock Traders Daily Direct company coverage

(PEN) Volatility Zones as Tactical Triggers

This article analyzes Penumbra Inc. (NYSE: PEN) using AI models, identifying neutral near and mid-term readings but a positive long-term bias. It outlines distinct institutional trading strategies, including position, momentum breakout, and risk hedging, tailored to different ris

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 10:10
Source
Stock Traders Daily
TradingView Direct company coverage

Enterprise value to EBITDA forward of Penumbra, Inc. – NYSE:PEN

This article provides the enterprise value to EBITDA forward for Penumbra, Inc. (NYSE: PEN). It indicates that the market was closed and no trades occurred at the time of publication, with data provided by ICE Data Services and FactSet.

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 06:10
Source
TradingView
MedTech Dive Direct company coverage

Penumbra starts trial of clot removal device in stroke subgroup

Penumbra has initiated a clinical trial to evaluate its RED reperfusion catheter portfolio for mechanical thrombectomy in patients with M2 occlusions, a subset of acute ischemic stroke. This study aims to inform treatment selection and potentially broaden the adoption of mechanic

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 15:40
Source
MedTech Dive
Barchart.com Direct company coverage

First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke

Penumbra, Inc. has initiated its FORWARD study, an international, multi-center study to evaluate the safety and efficacy of mechanical thrombectomy, including computer assisted vacuum thrombectomy (CAVT™), for distal acute ischemic stroke. The study, which has enrolled its first

Tone
Positive 71/100
Event
Market update
Published
07 Jul 2026 20:17
Source
Barchart.com
MassDevice Direct company coverage

Penumbra enrolls first patient in distal acute stroke thrombectomy study

Penumbra has initiated the FORWARD study to collect safety and efficacy data on its mechanical thrombectomy technology for distal acute ischemic stroke with M2 occlusions. The real-world, prospective, multi-center study will enroll up to 250 participants and evaluate Penumbra's R

Tone
Positive 76/100
Event
Market update
Published
07 Jul 2026 18:35
Source
MassDevice
Investing.com Direct company coverage

Penumbra initiates study on stroke treatment for distal occlusions

Penumbra Inc. has launched its FORWARD study, an international multi-center study investigating mechanical thrombectomy for acute ischemic stroke with distal occlusions. The study aims to collect safety and efficacy data on this treatment, evaluating Penumbra's RED reperfusion ca

Tone
Positive 69/100
Event
Market update
Published
07 Jul 2026 15:40
Source
Investing.com
DirectorsTalk Interviews Direct company coverage

Penumbra, Inc. (PEN) Stock Analysis: A Healthcare Innovator with a 14.40% Potential Upside

Penumbra, Inc. (NYSE: PEN) is a medical device company with a market cap of $12.53 billion, specializing in thrombectomy and embolization procedures. Analysts see a 14.40% potential upside with an average target price of $364.43, supported by strong revenue growth (15.60%) and a

Tone
Positive 86/100
Event
Earnings
Published
06 Jul 2026 09:10
Source
DirectorsTalk Interviews
TradingView Direct company coverage

Price to earnings forward of Penumbra, Inc. – DUS:0P8

This article provides financial data for Penumbra, Inc. (DUS:0P8) on the Dusseldorf Stock Exchange, specifically focusing on its forward Price to Earnings ratio. It presents an overview of the company's financials without detailed numbers, noting the market was closed at the time

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 06:10
Source
TradingView
Finviz Direct company coverage

PEN - Penumbra Inc Volatility & Greeks

This article provides a detailed financial overview of Penumbra Inc (PEN), including its latest stock performance, key financial metrics, volatility data, and analyst recommendations. It covers various fundamental and technical indicators, insider and institutional ownership, and

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jul 2026 23:09
Source
Finviz
www.dicardiology.com Direct company coverage

Penumbra Receives CE Mark for Reperfusion Catheters

Penumbra Inc. has received the CE Mark for its Red 72 Silver Label and Red 72 Silver Label with SENDit Technology reperfusion catheters, designed for acute ischemic stroke. These devices offer significant engineering updates for enhanced trackability and ease of navigation, build

Tone
Positive 75/100
Event
Market update
Published
02 Jul 2026 17:39
Source
www.dicardiology.com
NeuroNews International Direct company coverage

Penumbra secures European CE mark for Red 72 Silver Label technologies

Penumbra has received CE mark approval for its Red 72 Silver Label and Red 72 Silver Label with Sendit technology products in Europe. These reperfusion catheters, already available in the USA, offer significant updates for treating large vessel occlusion in acute ischemic stroke

Tone
Positive 74/100
Event
Regulatory and legal
Published
01 Jul 2026 13:41
Source
NeuroNews International
TradingView Direct company coverage

Penumbra, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh

This page provides an overview of financial actuals and estimates for Penumbra, Inc. (BMFBOVESPA:P2NB34), specifically for its Unsponsored Brazilian Depositary Receipt. Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash

Tone
Neutral 50/100
Event
Analyst action
Published
28 Jun 2026 02:39
Source
TradingView
TradingView Direct company coverage

PEN Forecast — Price Target — Prediction for 2027

This article provides a forecast for Penumbra, Inc. (PEN) stock, including analyst price targets, earnings estimates, and revenue projections. Analysts have provided 1-year price targets for PEN, with a maximum estimate of 6,593.79 MXN and a minimum estimate of 5,906.21 MXN. The

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 08:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Penumbra, Inc. – HAM:0P8

This page from TradingView focuses on the "Price to sales forward" financial metric for Penumbra, Inc. (HAM:0P8) on the Hamburg Stock Exchange. Although specific financial figures are not detailed, the page indicates that it provides human-made data and is part of TradingView's c

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 02:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Penumbra, Inc. – HAM:0P8

This article provides financial information for Penumbra, Inc. (HAM:0P8) on the Hamburg Stock Exchange, specifically focusing on its Price to Earnings Forward. The content presents an overview of the company's financials and includes metadata from TradingView.

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 16:41
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Penumbra, Inc. – NYSE:PEN

This article focuses on the "Price to sales forward" metric for Penumbra, Inc. (NYSE: PEN). It presents the company's financial data as provided by TradingView, detailing its market information and stock exchange listing. The content mainly consists of navigational links and copy

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 09:41
Source
TradingView
Morningstar Direct company coverage

Penumbra: Portfolio Expands With Approval To Treat Stroke; Acquisition by Boston on Track

Penumbra recently received US Food and Drug Administration approval and the CE Mark for its Thunderbolt computer-assisted vacuum aspiration system for ischemic stroke, expanding its portfolio. Concurrently, Boston Scientific is in the process of acquiring Penumbra. This developme

Tone
Positive 72/100
Event
Deals and strategy
Published
23 Jun 2026 01:10
Source
Morningstar
Investing.com Direct company coverage

Penumbra shareholders elect directors and approve executive pay at annual meeting

Penumbra Inc. shareholders met to elect three Class II directors to serve until the 2027 annual meeting, ratify PricewaterhouseCoopers LLP as the independent public accounting firm, and approve executive compensation. The medical device company also recently received CE Mark appr

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 00:26
Source
Investing.com
Investing.com Canada Direct company coverage

Form 8K Penumbra Inc For: 22 June By Investing.com

This article announces that Penumbra Inc. filed a Form 8K for June 22. The article is very brief, serving mainly as a headline with no additional details about the filing's content. It also includes stock market data and other news.

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 00:00
Source
Investing.com Canada
Morningstar Direct company coverage

Penumbra Expands Portfolio With Approval To Treat Stroke; Acquisition by Boston on Track

Penumbra, a company specializing in endovascular systems for blood clots and aneurysms, has received approval to treat stroke. This development comes as the company is on track to be acquired by Boston Scientific by the end of 2026. Penumbra has built a growing presence in the th

Tone
Neutral 50/100
Event
Deals and strategy
Published
22 Jun 2026 18:40
Source
Morningstar
Stock Traders Daily Direct company coverage

(PEN) Price Dynamics and Execution-Aware Positioning

This article provides an AI-driven analysis for Penumbra Inc. (NYSE: PEN), indicating a neutral near and mid-term outlook with a moderating long-term positive bias and elevated downside risk. It details various trading strategies—position, momentum breakout, and risk hedging—alon

Tone
Neutral 50/100
Event
Guidance
Published
21 Jun 2026 07:10
Source
Stock Traders Daily